Short Interest in VolitionRX Limited (NYSEAMERICAN:VNRX) Grows By 46.6%

VolitionRX Limited (NYSEAMERICAN:VNRX) saw a large increase in short interest in February. As of February 13th, there was short interest totaling 2,294,782 shares, an increase of 46.6% from the January 29th total of 1,565,335 shares. Based on an average daily volume of 2,140,767 shares, the short-interest ratio is currently 1.1 days. Currently, 1.9% of the shares of the stock are sold short. Currently, 1.9% of the shares of the stock are sold short. Based on an average daily volume of 2,140,767 shares, the short-interest ratio is currently 1.1 days.

VolitionRX Trading Down 9.4%

Shares of NYSEAMERICAN VNRX traded down $0.02 during midday trading on Friday, reaching $0.21. The company’s stock had a trading volume of 1,282,495 shares, compared to its average volume of 2,304,187. VolitionRX has a one year low of $0.17 and a one year high of $0.94. The company has a market cap of $28.88 million, a price-to-earnings ratio of -0.93 and a beta of 1.29. The company has a 50 day moving average price of $0.26 and a 200 day moving average price of $0.41.

About VolitionRX

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.